G protein-coupled receptors

Global Axial Spondyloarthritis (axSpA) Market Spotlight 2021-2031: Marketed & Pipeline Dugs, Clinical Trials, Regulatory Events, Probability of Success, Disease Prevalence, Revenues - ResearchAndMarkets.com

Monday, June 14, 2021 - 11:07am

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, interleukin 17, IL-17 receptor, and JAK/STAT.
  • The greatest proportion of industry-sponsored drugs in active clinical development for axSpA are in the NDA/BLA phase.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for ankylosing spondylitis, followed by AbbVie

Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)

Wednesday, June 9, 2021 - 1:43pm

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE).

Key Points: 
  • Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE).
  • Etrasimod is an investigational compound that is not approved for any use in any country.
  • ARENA Pharmaceuticals is a team with a singular purpose deliver important medicines to patients.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Wednesday, June 9, 2021 - 3:31am

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Tectonic Therapeutic Appoints Peter McNamara, PhD Senior Vice President, Head of Research

Thursday, May 27, 2021 - 12:00pm

Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.

Key Points: 
  • Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.
  • We welcome Peter as a key member of our leadership team at Tectonic.
  • Tectonic has the technology and the experienced team to expand and accelerate the development of GPCR-targeted therapies with biologics, said Dr. McNamara.
  • The GEODe platform that Tectonic has developed is incredibly exciting and can be utilized to develop drugs that improve patient care across a number of therapeutic areas.

Global Sphingosine 1 Phosphate Receptor Modulators Pipeline Insights Market Report 2021 - ResearchAndMarkets.com

Tuesday, May 11, 2021 - 12:50pm

b'The "Sphingosine 1 Phosphate Receptor Modulators - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2021 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Sphingosine 1 phosphate receptor modulators pipeline landscape.

Key Points: 
  • b'The "Sphingosine 1 Phosphate Receptor Modulators - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2021 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Sphingosine 1 phosphate receptor modulators pipeline landscape.
  • The drug is currently in phase 3 of clinical trials for the treatment of Atopic dermatitis; Ulcerative colitis.\nSphingosine 1 phosphate receptor modulators: Therapeutic Assessment\nThis segment of the report provides insights about the different Sphingosine 1 phosphate receptor modulators drugs segregated based on following parameters that define the scope of the report, such as:\nThere are approx.
  • The companies which have their Sphingosine 1 phosphate receptor modulators drug candidates in the most advanced stage, i.e.
  • phase III include, Arena Pharmaceuticals.\nSphingosine 1 phosphate receptor modulators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.\n'

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results

Monday, May 10, 2021 - 9:05pm

Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs).

Key Points: 
  • Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs).
  • For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995.
  • Actual events or results may differ materially from Longboard\xe2\x80\x99s expectations.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.\n'

RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®

Wednesday, May 5, 2021 - 3:50pm

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).

Key Points: 
  • Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).
  • Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients.
  • \xe2\x80\x9cThe Phase III results demonstrate the high sensitivity, specificity, and accuracy of Detectnet.
  • In published trials nausea immediately after injection was observed.\nNon-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®

Wednesday, May 5, 2021 - 7:30am

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).

Key Points: 
  • Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).
  • Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients.
  • \xe2\x80\x9cThe Phase III results demonstrate the high sensitivity, specificity, and accuracy of Detectnet.
  • In published trials nausea immediately after injection was observed.\nNon-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

Global Sphingosine 1-Phosphate Receptor (S1PR) Drugs Development Market Report 2021: Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

Thursday, April 29, 2021 - 10:29am

b'The "Sphingosine 1-Phosphate Receptor (S1PR) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nSphingosine 1-Phosphate Receptor (S1PR) - Drugs in Development, 2021 provides in depth analysis on Sphingosine 1-Phosphate Receptor (S1PR) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points: 
  • b'The "Sphingosine 1-Phosphate Receptor (S1PR) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nSphingosine 1-Phosphate Receptor (S1PR) - Drugs in Development, 2021 provides in depth analysis on Sphingosine 1-Phosphate Receptor (S1PR) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics development and features dormant and discontinued projects.
  • The report analyses the pipeline products across relevant therapy areas under development targeting Sphingosine 1-Phosphate Receptor (S1PR).\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which include Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor (S1PR) targeted therapeutics.\n'

In-depth Analysis on Proto Oncogene Mas (MAS1) Targeted Pipeline Therapeutics, 2021 Market Report - ResearchAndMarkets.com

Wednesday, April 28, 2021 - 10:38am

b'The "Proto Oncogene Mas (MAS1) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nProto Oncogene Mas (MAS1) - Drugs in Development, 2021 provides in depth analysis on Proto Oncogene Mas (MAS1) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points: 
  • b'The "Proto Oncogene Mas (MAS1) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nProto Oncogene Mas (MAS1) - Drugs in Development, 2021 provides in depth analysis on Proto Oncogene Mas (MAS1) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in Proto Oncogene Mas (MAS1) targeted therapeutics development and features dormant and discontinued projects.
  • The report analyses the pipeline products across relevant therapy areas under development targeting Proto Oncogene Mas (MAS1).\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews Proto Oncogene Mas (MAS1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in Proto Oncogene Mas (MAS1) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses Proto Oncogene Mas (MAS1) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to Proto Oncogene Mas (MAS1) targeted therapeutics.\n'